NewAmsterdam Pharma publishes obicetrapib Alzheimer’s prevention research presentation

PUBT · 1d ago
NewAmsterdam Pharma publishes obicetrapib Alzheimer’s prevention research presentation
  • NewAmsterdam Pharma published a research presentation on CETP inhibition for Alzheimer’s prevention, centered on its CETP inhibitor obicetrapib.
  • In the Phase 3 BROADWAY AD biomarker substudy, 12 months of obicetrapib reduced plasma p-tau217 versus placebo, strongest in APOE4/E4 carriers.
  • The presentation also cited favorable shifts across other Alzheimer’s-related biomarkers, supporting a rationale for prevention trials in at-risk APOE4 populations.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NewAmsterdam Pharma Company NV published the original content used to generate this news brief on July 16, 2026, and is solely responsible for the information contained therein.